UNLABELLED: Organic solute transporter alpha-beta (Ostalpha-Ostbeta) is a heteromeric bile acid and sterol transporter that facilitates the enterohepatic and renal-hepatic circulation of bile acids. Hepatic expression of this basolateral membrane protein is increased in cholestasis, presumably to facilitate removal of toxic bile acids from the liver. In this study, we show that the cholestatic phenotype induced by common bile duct ligation (BDL) is reduced in mice genetically deficient in Ostalpha. Although Ostalpha(-/-) mice have a smaller bile acid pool size, which could explain lower serum and hepatic levels of bile acids after BDL, gallbladder bilirubin and urinary bile acid concentrations were significantly greater in Ostalpha(-/-) BDL mice, suggesting additional alternative adaptive responses. Livers of Ostalpha(-/-) mice had higher messenger RNA levels of constitutive androstane receptor (Car) than wild-type BDL mice and increased expression of Phase I enzymes (Cyp7a1, Cyp2b10, Cyp3a11), Phase II enzymes (Sult2a1, Ugt1a1), and Phase III transporters (Mrp2, Mrp3). Following BDL, the bile acid pool size increased in Ostalpha(-/-) mice and protein levels for the hepatic basolateral membrane export transporters, multidrug resistance-associated protein 3 (Mrp3) and Mrp4, and for the apical bilirubin transporter, Mrp2, were all increased. In the kidney of Ostalpha(-/-) mice after BDL, the apical bile acid uptake transporter Asbt is further reduced, whereas the apical export transporters Mrp2 and Mrp4 are increased, resulting in a significant increase in urinary bile acid excretion. CONCLUSION: These findings indicate that loss of Ostalpha provides protection from liver injury in obstructive cholestasis through adaptive responses in both the kidney and liver that enhance clearance of bile acids into urine and through detoxification pathways most likely mediated by the nuclear receptor Car.
UNLABELLED: Organic solute transporter alpha-beta (Ostalpha-Ostbeta) is a heteromeric bile acid and sterol transporter that facilitates the enterohepatic and renal-hepatic circulation of bile acids. Hepatic expression of this basolateral membrane protein is increased in cholestasis, presumably to facilitate removal of toxic bile acids from the liver. In this study, we show that the cholestatic phenotype induced by common bile duct ligation (BDL) is reduced in mice genetically deficient in Ostalpha. Although Ostalpha(-/-) mice have a smaller bile acid pool size, which could explain lower serum and hepatic levels of bile acids after BDL, gallbladder bilirubin and urinary bile acid concentrations were significantly greater in Ostalpha(-/-) BDL mice, suggesting additional alternative adaptive responses. Livers of Ostalpha(-/-) mice had higher messenger RNA levels of constitutive androstane receptor (Car) than wild-type BDL mice and increased expression of Phase I enzymes (Cyp7a1, Cyp2b10, Cyp3a11), Phase II enzymes (Sult2a1, Ugt1a1), and Phase III transporters (Mrp2, Mrp3). Following BDL, the bile acid pool size increased in Ostalpha(-/-) mice and protein levels for the hepatic basolateral membrane export transporters, multidrug resistance-associated protein 3 (Mrp3) and Mrp4, and for the apical bilirubin transporter, Mrp2, were all increased. In the kidney of Ostalpha(-/-) mice after BDL, the apical bile acid uptake transporter Asbt is further reduced, whereas the apical export transporters Mrp2 and Mrp4 are increased, resulting in a significant increase in urinary bile acid excretion. CONCLUSION: These findings indicate that loss of Ostalpha provides protection from liver injury in obstructive cholestasis through adaptive responses in both the kidney and liver that enhance clearance of bile acids into urine and through detoxification pathways most likely mediated by the nuclear receptor Car.
Authors: M Trauner; M Arrese; C J Soroka; M Ananthanarayanan; T A Koeppel; S F Schlosser; F J Suchy; D Keppler; J L Boyer Journal: Gastroenterology Date: 1997-07 Impact factor: 22.682
Authors: Catherine A M Stedman; Christopher Liddle; Sally A Coulter; Junichiro Sonoda; Jacqueline G A Alvarez; David D Moore; Ronald M Evans; Michael Downes Journal: Proc Natl Acad Sci U S A Date: 2005-01-31 Impact factor: 11.205
Authors: Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz Journal: Mol Cell Biol Date: 2004-09 Impact factor: 4.272
Authors: Mahfoud Assem; Erin G Schuetz; Markos Leggas; Daxi Sun; Kazuto Yasuda; Glen Reid; Noam Zelcer; Masashi Adachi; Stephen Strom; Ronald M Evans; David D Moore; Piet Borst; John D Schuetz Journal: J Biol Chem Date: 2004-03-05 Impact factor: 5.157
Authors: Grace L Guo; Gilles Lambert; Masahiko Negishi; Jerrold M Ward; H Bryan Brewer; Steven A Kliewer; Frank J Gonzalez; Christopher J Sinal Journal: J Biol Chem Date: 2003-08-15 Impact factor: 5.157
Authors: C Gartung; M Ananthanarayanan; M A Rahman; S Schuele; S Nundy; C J Soroka; A Stolz; F J Suchy; J L Boyer Journal: Gastroenterology Date: 1996-01 Impact factor: 22.682
Authors: Simrat P S Saini; Junichiro Sonoda; Li Xu; David Toma; Hirdesh Uppal; Ying Mu; Songrong Ren; David D Moore; Ronald M Evans; Wen Xie Journal: Mol Pharmacol Date: 2004-02 Impact factor: 4.436
Authors: Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl Journal: J Hepatol Date: 2014-02-19 Impact factor: 25.083
Authors: Jittima Weerachayaphorn; Albert Mennone; Carol J Soroka; Kathy Harry; Lee R Hagey; Thomas W Kensler; James L Boyer Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-02-16 Impact factor: 4.052